


1. Growth Hormone (GH) Stimulating Agents MOA: Stimulation of release and replacement of GH <i>Somatropin</i> – GH - SE: Hyperglycemia, carpal tunnel syndrome <i>Tesamorelin</i> – Synthetic GHRH, visceral adiposity in HIV patients <i>Mecasermin</i> – Recombinant IGF-1 - SE: Hypoglycemia, LV hypertrophy CI: Malignancies	3. Prolactin reducing agents (Dopamine Agonists) MOA: Reduce Prolactin Release <i>Bromocriptine/Cabergoline</i> – Dopamine agonists (D ₂) SE: psychosis, ↓GH, ↓GnRH	5. Vasopressin agonists – TX: Diabetes insipidus MOA: Activates V ₁ and V ₂ receptors <i>Vasopressin</i> – Esophageal variceal bleeding <i>Desmopressin</i> – V ₂ >V ₁ -VWb disease, nocturnal enuresis SE: Headache, nausea, cramps agitation, allergic reactions	7. Thyroid Hormone therapy – TX: Hypothyroidism MOA: Synthetic thyroid hormone replacement <i>Levothyroxine</i> – Synthetic T ₄ – LONG T1/2 <i>Liothyronine</i> – Synthetic T ₃ – More potent form <i>Liotrix</i> – T ₃ & T ₄ SE: Weight loss, tachycardia, heat intolerance, insomnia CI: PPIs, Bisphosphonates, Cholestryamine, Warfarin, Digoxin, Amiodarone, Oral contraceptives, Myxedema, Coronary Artery Disease
2. Growth Hormone (GH) Reducing Agents MOA: Blockade of GH release or receptor <i>Pegvisomant</i> – GH-R antagonist - SE: ↑CYPs, lipodystrophy <i>Octreotide, Lantreotide</i> – somatostatin analog - SE: B12 deficiency (↓GI motil.), ↓ insulin release <i>Bromocriptine/Cabergoline</i> – D ₂ agonist – SE: psychosis, ↓PRL, ↓TRH, ↓GnRH	4. Oxytocin agents MOA: Modulate OT receptors during Delivery 4A. Pitocin – Oxytocin agonist - Must conduct Fetal tolerance test SE: Uterine contractions, fetal distress 4b. Atosaban – Oxytocin receptor antagonist – prevent preterm labor	6. Vasopressin Antagonists – TX: SIADH MOA: Antagonism of V ₁ and V ₂ receptors <i>Conivaptan</i> – V _{1a} and V ₂ Receptors – IV administration <i>Tolvaptan</i> – V ₂ > V ₁ Receptors – Oral SE: Hepatotoxicity (tolvaptan)	8. Anti-Hyperthyroid Agents MOA: Antagonism of V ₁ and V ₂ receptors 8a. Thioamides – <i>Methimazole, PTU</i> MOA: Inhibit Thyroid Peroxidase–Block Organification SE: GI, rash, arthralgia, agranulocytosis, liver toxicity CI: pregnancy – Can be used for only the 1 st trimester 8b. Anion inhibitors – <i>perchlorate, thiocyanate</i> MOA: Competitively Inhibit Thyroid Iodine transport 8c. Radioactive Iodine – <i>I¹³¹</i> MOA: Emits B particle to destroy thyroid tissue CI: pregnancy – cretinism 8d. Iodides – <i>Lugol's Solution</i> MOA: inhibits organification and hormone release



9. Corticosteroids MOA: Activate nuclear steroid receptors <i>Fludrocortisone</i> – mineralocorticosteroids <i>Hydrocortisone, Betamethasone</i> – Glucocorticosteroids <i>Cortisol, Prednisone</i> – Mixed gluco/mineralocorticosteroid SE: Mineralocorticosteroids – Fluid retention ↑Na ⁺ , ↓K ⁺ Glucocorticosteroids – Hyperglycemia, Peptic ulcer, infection, Bone resorption, moon face, buffalo hump	10. Mineralocorticosteroid (MCS) receptor antagonists MOA: Inhibit MCS receptors <i>Spironolactone</i> – MCS/androgen antag. SE: ↓Libido, amenorrhea, tender breasts, metabolic acidosis <i>Eplerenone</i> – MCS antagonist SE: Hypotension, diuresis <i>Drospirenone</i> (Progesterin) – MCS/androgen antag. SE: ↓Libido CI: RAAS inhibitors (hyperkalemia), K-supplements	11. Corticosteroid synthesis inhibitors MOA: Inhibit steroid synthesis <i>Aminoglutethimide</i> – Inhibits cholesterol to pregnenolone SE: Hepatotoxic, Rash, hypothyroid <i>Ketoconazole</i> – inhibits side chain cleavage SE: Inhibits CYPs, impotence, Long QT <i>Metyrapone</i> – Inhibits 11-β-Hydroxylase <i>Etomide</i> – Adrenal suppression	12. Corticosteroid Receptor Antagonists MOA: Block corticosteroid receptor activation <i>Mifepristone</i> – USE: Adrenal carcinoma, ectopic ATCH secretion SE: Fetal Death, Long QT, Hypertension CI: pregnancy
---	---	--	---